UCMOK
BCTX

United Capital Management of KS’s Briacell Therapeutics BCTX Stock Holding History

United Capital Management of KS’s Portfolio BCTX Stock Details BCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-102
Closed -$8.62K – 94
2024
Q4 		$8.62K Buy
+102
New +$12.2K ﹤0.01% 87

Other funds holding BCTX

UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
National Bank of Canada
National Bank of Canada Montreal, Quebec, Canada $140B AUM 46.34% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CWP
Concord Wealth Partners Abingdon, Virginia $873M AUM 24.02% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
HWA
HHM Wealth Advisors Chattanooga, Tennessee $996M AUM 23.11% 1-Year Est. Return

United Capital Management of KS's BCTX Position: Q1 2025 in Review

United Capital Management of KS sold out of Briacell Therapeutics (BCTX) in Q1 2025, closing a stake of 102 shares — an estimated $8.62K sold.

United Capital Management of KS first reported a position in BCTX in Q4 2024 and held it in 1 quarter. The position peaked at $8.62K in Q4 2024. 13 funds tracked by Wall St. Rank hold BCTX as of Q1 2025.

  • United Capital Management of KS reported no remaining Briacell Therapeutics position as of Q1 2025 after selling out during the quarter.
  • United Capital Management of KS sold 102 Briacell Therapeutics shares in Q1 2025, an estimated $8.62K.
  • United Capital Management of KS first reported a position in Briacell Therapeutics in Q4 2024 and held it in 1 quarter.
  • United Capital Management of KS's Briacell Therapeutics position peaked at $8.62K in Q4 2024.
  • 13 funds tracked by Wall St. Rank held Briacell Therapeutics as of Q1 2025.

Based on United Capital Management of KS's 13F filing for Q1 2025, filed 13 May 2025.